ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / IPHA / insiders
ABOS (38) IVVD (30) STRO (36) TARA (43) ⌘ Pro Terminal →

Innate Pharma S.A. ADS (IPHA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.46 -2.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.45

Innate Pharma S.A. ADS (IPHA) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $167.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IPHA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IPHA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Innate Pharma S.A. ADS (NASDAQ: IPHA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.46 (-2.67% 1D, market cap $167.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IPHA ranks #271 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IPHA compare to ABOS and IVVD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPHA carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M) and IVVD (Invivyd Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.4M). Among the 5-stock peer group, IPHA leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IPHA?
▼

For Innate Pharma S.A. ADS (IPHA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #271 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.45 (-0.67%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510052
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (8)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE IPHA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IPHA)Realized 20D OHLCV Swing Band: ±12.1%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY IPHA SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
60
Grade C$1.62-11.7% Next Q
Q2 (-2Q)
57
Grade C$1.43+4.9% Next Q
Q3 (-1Q)
55
Grade C$1.50-2.7% Next Q
Current
52
Grade D+$1.46-1.1% Hist 90D α
Trajectory: C (60) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IPHA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IPHA currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.77) and Max Pain ($1.53) forces dealer call-delta covering toward $2.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IPHA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IPHA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 52%NO 48%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

IPHA Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (IPHA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on IPHA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IPHA)

  • ✓Walkthrough of IPHA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IPHA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.39%🛡️ HOLDING TREND SUPPORT
2026-10-30O $1.45H $1.48L $1.44C $1.46VOL 14.8K
RES: $2.79SUP: $1.39SMA50: $1.77SMA200: $1.71
$2.81$2.40$2.00$1.60$1.19RES $2.79SUP $1.39$1.462026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IPHA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IPHA Butterfly Map → + Track IPHA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IPHA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IPHA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IPHA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IPHA)

Health Care Rank #271 of 1016 ⚔️ ABOS vs IPHA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IPHA vs. ABOS, IVVD, STRO, TARA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Innate Pharma S.A. ADS (IPHA) ranks #271 by composite RQD confidence (52/100, grade D+) and #598 by equity capitalization ($167.6M). Within this direct 5-issuer industry benchmark cohort, IPHA leads on earnings valuation at N/A trailing P/E, while TARA leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. IPHA currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IPHA ACTIVE
Innate Pharma S.A. ADS
D+ 52/100 — — — -2.67% $167.6M Benchmark Subject
ABOS
Acumen Pharmaceuticals Inc.
D- 38/100 — — -35.0% -90.82% $165.6M /abos-vs-ipha →
IVVD
Invivyd Inc.
E 30/100 — — -35.0% -3.37% $177.4M /ivvd-vs-ipha →
STRO
Sutro Biopharma Inc.
D- 36/100 — — -35.0% -0.44% $151.6M /stro-vs-ipha →
TARA
Protara Therapeutics Inc.
D- 43/100 — — -34.7% -1.59% $148.9M /tara-vs-ipha →

2. IPHA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Innate Pharma S.A. ADS (IPHA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $167.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IPHA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IPHA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Innate Pharma S.A. ADS (NASDAQ: IPHA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.46 (-2.67% 1D, market cap $167.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IPHA ranks #271 in composite RQD confidence.

How does IPHA compare to ABOS and IVVD in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPHA carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M) and IVVD (Invivyd Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.4M). Among the 5-stock peer group, IPHA leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IPHA?

For Innate Pharma S.A. ADS (IPHA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #271 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IPHA trading relative to its 50-day, 200-day, and 52-week technical levels?

IPHA last traded at $1.46 (-2.67% on volume of 14,784 shares), positioning the stock -17.51% below its 50-day simple moving average ($1.77) and -14.62% below its 200-day simple moving average ($1.71). Across its 52-week range of $1.17 to $2.71, IPHA sits at the 18.8% percentile with a 14-day RSI of 40.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($1.28 to $1.64).

IPHA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are IPHA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies IPHA leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: IPHA RQD Cockpit IPHA 12M Forecast IPHA Earnings & Move IPHA Dividends & DRIP IPHA Insiders & 13F IPHA Whale Options IPHA Profit Sankey IPHA News & Why
ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IPHA — Innate Pharma S.A. ADS: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline
As of: 2026-11-02T14:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Innate Pharma S.A. ADS (IPHA) carries a composite score of 52/100 (D+ — Roarable Sell — Weak Fundamentals / Trim) at a current price of $1.46 (-2.67%). Fundamental cash generation scores 12/20 (ROIC —, FCF yield —), institutional 13F whale accumulation scores 8/20, insider conviction scores 9/20, macro regime alignment scores 10/20 (Beta 1.00), and forensic balance-sheet protection scores 13/20 (Altman Z-Score N/A, Piotroski F-Score N/A).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Biological Products (No Diagnostic Substances), upside depends on sustained operating margin expansion (—) and free cash flow conversion relative to the 52-week range of $1.17 – $2.71.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), IPHA is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

IPHA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Innate Pharma S.A. ADS (IPHA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IPHA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IPHA Bull vs. Bear Conversation Board — What's Your Call at $1.46?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IPHA 🐻 50% BEARISH CONVICTION
1. Pick Your Side on IPHA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.58 (+8.2%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IPHA (D+ • RQD 52/100) a Buy at $1.46?

Welcome to the IPHA (Innate Pharma S.A. ADS) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.12 (-23.3%)
Spot @ $1.46

Pump the brakes on IPHA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IPHA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Innate Pharma S.A. ADS expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.69 (+15.8%)
Spot @ $1.46

IPHA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IPHA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.46 (52-wk range $1.17 - $2.71), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%